Test Price
2,800 AED✅ Home Collection Available
SMARCE1 Gene Familial Meningioma Susceptibility NGS Test in UAE | 2800 AED | DHA Licensed & Accredited
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 and ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy with Hospital-Grade Cold-Chain Home Collection from 8 AM to 11 PM daily.
- Clinical Guidance: Complimentary Telephonic Post-Test Interpretation by DHA-Licensed Genetic Counsellors.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731. All major UAE medical networks accepted.
- Turnaround Time: 3–4 Weeks including dry-lab tertiary analysis and clinical reporting.
Test Overview & Methodology
The SMARCE1 NGS panel detects pathogenic variants in the SMARCE1 gene conferring autosomal dominant susceptibility to familial meningioma. This DHA-aligned assay empowers oncologists and genetic counsellors with actionable data for early surveillance, risk stratification, and informed family counselling. Full exon coverage ensures detection of single nucleotide variants, small insertions, and deletions with high analytical sensitivity.
| Feature | Our Test – DNA Labs UAE | Closest Alternative |
|---|---|---|
| Methodology | Next-Generation Sequencing – full exon coverage with copy-number variant detection | Sanger Sequencing limited to known familial variants |
| Analytical Sensitivity | Greater than 99.9% for single nucleotide variants and small indels | Approximately 99.0% restricted to targeted regions |
| Turnaround Time | 3–4 Weeks including tertiary analysis and clinical correlation | 6–8 Weeks when referred to overseas laboratories |
| Sample Types | Whole Blood, Extracted DNA, or FTA Card Blood Spot | Whole Blood only |
| Pre-Test Requirement | Genetic Counselling and Pedigree Chart included in service | Not systematically provided |
Physician Insight & Safety Protocols
A Note from Lina Osama Zaki Quteineh – Consultant Medical Genetics | DHA Registration ID: 9294403
Identification of a pathogenic SMARCE1 variant provides critical information for early surveillance and family counselling. However, this genetic finding must always be interpreted alongside clinical presentation and neuroimaging data. I recommend all patients undergo pre-test and post-test genetic counselling to fully understand the implications for themselves and their family members.
Medication Safety Advisory
Never alter or stop prescribed medications—including corticosteroids, anticonvulsants, or any neurological therapy—without direct approval from your treating physician. Sudden discontinuation may lead to serious neurological deterioration or rebound symptoms.
Exclusion Criteria and Emergency Red Flags
Exclusion Criteria – Do not proceed without physician clearance:
- Acute neurological deterioration including seizure, severe headache, or focal deficit
- Current pregnancy – requires separate genetic counselling pathway
- Active hemolysis or blood transfusion within the past four weeks
- Inability to provide informed consent – minors require guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability
Seek immediate emergency care if you experience:
- Sudden vision loss or double vision
- Worsening hearing loss or persistent tinnitus
- New-onset seizures or convulsions
- Progressive limb weakness or facial droop
Patient FAQ & Clinical Guidance
1. What is the SMARCE1 gene and why is it tested for familial meningioma?
The SMARCE1 gene encodes a chromatin remodeling protein essential for normal cellular regulation. Pathogenic variants cause an autosomal dominant predisposition to multiple meningiomas. Testing enables early surveillance and risk management for individuals with a relevant family history of meningioma or related tumours.
2. How is the blood sample collected and what is the turnaround time?
A certified phlebotomist collects a blood sample onto an FTA card or in an EDTA tube at your home or a designated hospital facility. The specimen is transported under temperature-controlled cold chain logistics. Results are delivered within three to four weeks and include a complimentary telephonic interpretation session with a DHA-licensed genetic counsellor.
3. Can this test be performed on children or minors in the UAE?
Yes, genetic testing for minors is permitted under UAE law when accompanied by documented guardian consent and a pre-test genetic counselling session as required by Federal Decree-Law No. 4 of 2016 on Medical Liability. The referring physician must also confirm medical necessity before sample collection proceeds.
4. What do the results mean for my family members?
A pathogenic SMARCE1 variant has autosomal dominant inheritance, meaning first-degree relatives have a 50% chance of carrying the same variant. Cascade screening for at-risk family members is strongly recommended. Our genetic counselling team can guide you and your relatives through the testing and disclosure process.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143 and complies fully with UAE federal data protection and health information governance frameworks. All genetic data is processed, stored, and transmitted in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety, informed consent, and patient rights are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic information remains confidential and is never shared with third parties without your explicit written authorization.
Clinical & Logistical Metadata
| Test Name | SMARCE1 Gene Familial Meningioma Susceptibility NGS Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or FTA Card Blood Spot – VIP Mobile Phlebotomy and Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Next-Generation Sequencing – full exon coverage with copy-number variant analysis |
| ICD-10-CM Code | Z15.09 |
| LOINC Code | 95819-4 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians